http://localhost:8080/xmlui/handle/123456789/12239 2026-04-09T07:05:16Z 2026-04-09T07:05:16Z Marsigit, Jessica Moenardi, Valentine Natasya Putranto, Rudi Shatri, Hamzah Irvianita, Vinandia Faisal, Edward http://localhost:8080/xmlui/handle/123456789/12257 2025-07-21T02:19:27Z 2025-01-01T00:00:00Z

Title: The Aging Population and Dementia: The Need for Comprehensive Palliative Care Authors: Marsigit, Jessica; Moenardi, Valentine Natasya; Putranto, Rudi; Shatri, Hamzah; Irvianita, Vinandia; Faisal, Edward Abstract: Dementia is a progressive condition that gradually impairs cognitive function, memory, and daily living skills. This disease not only impacts the individual but also has significant consequences for their families and caregivers. The global prevalence of dementia is on the rise, including in Indonesia. It's estimated that approximately 1.2 million people in Indonesia are currently living with dementia, a number projected to quadruple by 2050. Patients with dementia often experience a range of symptoms and complications, including pain, difficulty eating, shortness of breath, and susceptibility to infections. For those in advanced stages of the disease, family and caregivers play a crucial role in their well-being. However, this role can be emotionally taxing, making support essential. Palliative care offers a promising approach to enhancing the quality of life for both dementia patients and their families. By prioritizing symptom management, psychological support, and respecting patient autonomy, palliative care can help alleviate suffering and promote well-being throughout the disease's progression.

2025-01-01T00:00:00Z Antono, Dono Gautama, Ade Utami, Nindya P.B.S. http://localhost:8080/xmlui/handle/123456789/12256 2025-07-21T02:17:12Z 2025-01-01T00:00:00Z

Title: Anti-inflammatory Therapy Before Reperfusion Therapy in Patients with Ischemic Vascular Disease on the Incidence of Ischemic Reperfusion Injury: An Evidence-Based Case Report Authors: Antono, Dono; Gautama, Ade; Utami, Nindya P.B.S. Abstract: Background: Reperfusion serves as a mainstay therapy in almost all ischemic vascular diseases (IVD), but reperfusion may enhance cell damage after an ischemic period time. Increased ROS and inflammatory markers, decreasing organ function parameters, along with systemic inflammatory response and multi-organ damage may occur in ischemic reperfusion injury (IRI). Unfortunately, this series of events is unpredictable and sudden, causing high mortality in patients with IRI. Due to the significant role of inflammation in IRI, how is the effectiveness of anti-inflammatory agents administered before reperfusion therapy to prevent IRI? To know the efficacy of anti-inflammatory agents administered before reperfusion therapy to prevent IRI. Methods: A systematic search was conducted in databases (Pubmed, EMBASE, Scopus) and was later selected according to predetermined inclusion and exclusion criteria. Studies included later critically appraised using the CEBM Oxford questionnaire for randomized control trials and systematic review. Results: Seven studies were included among 1072 studies found in early searching. Six of the studies are randomized control trials, and one is a metaanalysis of randomized control trials. Methylprednisolone, pexelizumab, tirilazad mesylate, and N-acetylcysteine are known anti-inflammatory agents applicable in humans. The highest effectiveness of anti-inflammatory agents is methylprednisolone, with a relative risk reduction (RRR) of 75-85%. Besides that, pexelizumab also had an RRR of 27%, and tirilazad-mesylate had an RRR of 18%. N-acetylcysteine is not effective in preventing IRI. IL-6 levels postoperatively also decreased significantly in patients given anti-inflammatory agents before reperfusion therapy. There are no side effects of the intervention reported. Conclusion: Anti-inflammatory agent administration before reperfusion therapy effectively prevents IRI. The choices of anti-inflammatory agents recommended are methylprednisolone, pexelizumab, and tirilazad-mesylate. Anti-inflammatory agent administration before reperfusion therapy is recommended.

2025-01-01T00:00:00Z Yanto, Theo Audi Tobing, Edwin Raja P.L. Herijanto, Billie Edgara Liem, Jean Andrina Sabran, Mohammad Zuhriansyah http://localhost:8080/xmlui/handle/123456789/12255 2025-07-21T02:14:48Z 2025-01-01T00:00:00Z

Title: Scrofuloderma of the Penis: Unveiling a Rare Case of Cutaneous Tuberculosis Authors: Yanto, Theo Audi; Tobing, Edwin Raja P.L.; Herijanto, Billie Edgara; Liem, Jean Andrina; Sabran, Mohammad Zuhriansyah

2025-01-01T00:00:00Z He, Qiaoya An, Jiaqi Liu, Xinze Zhuo, Li http://localhost:8080/xmlui/handle/123456789/12254 2025-07-21T02:12:34Z 2025-01-01T00:00:00Z

Title: The Role of Vitamin D and Its Receptor Signaling in Diabetic Nephropathy and the Current Status of Research: A Literature Review Authors: He, Qiaoya; An, Jiaqi; Liu, Xinze; Zhuo, Li Abstract: Diabetic kidney disease (DKD) is one of the common and serious complications of diabetes mellitus, with a complex pathogenesis and a lack of ideal treatment options in clinical practice. In recent years, the protective role of vitamin D and its receptor signaling pathway in DKD has garnered widespread attention. Vitamin D plays an important role in the onset and progression of DKD by participating in the regulation of insulin secretion, inhibiting inflammatory responses, attenuating podocyte injury, modulating the renin-angiotensin system (RAS), and inhibiting renal interstitial fibrosis through its receptor (VDR). Studies on the use of vitamin D and its receptors in DKD have increased gradually in recent years, with a focus on the development of vitamin D analogs and the clinical application of VDR activators. This study reviewed the mechanisms of vitamin D and its receptor in diabetic nephropathy, as well as the potential for therapeutic applications and associated adverse effects. It also analyzed current research hotspots and development trends based on bibliometrics. Future research should focus on further optimizing vitamin D-based therapeutic strategies to achieve better clinical efficacy and safety

2025-01-01T00:00:00Z